N
Neurovance
Clinical stage neuroscience company
About Neurovance
Neurovance, a subsidiary of Otsuka, operates within the pharmaceutical industry, focusing on the research and development of innovative pharmaceutical products and digital medicine. The company primarily serves patients with neurological and psychological conditions, including Attention Deficit Hyperactivity Disorder (ADHD). Neurovance's business model revolves around the development and commercialization of new drugs and digital health solutions, aiming to improve patient outcomes and overall health. The company generates revenue through the sale of its pharmaceutical products and digital health services, targeting healthcare providers, caregivers, and patients. Neurovance operates in a highly competitive market, leveraging its extensive research capabilities and global network of affiliated companies to maintain a leading position in the industry.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Open positions
- None listed
- Dealroom signal
- 53.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Neurovance.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2017 | $250M | $250M | Undisclosed | — |
| DEBT✓Debt | Jul 2016 | $6M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Neurovance is 240 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
State of Wisconsin Investment Board
Novartis Venture Fund
Series A2 investors entered at this stage
Venture Investors Health Fund- TMTekla Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurovance on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurovance’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.